Tempest Therapeutics, Inc. (TPST) annual income statement — 14-year revenue, gross profit & net income history
Tempest Therapeutics, Inc. (TPST) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 295K | 653K | 277K | 9.73M | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | -100% | -54.82% | 135.74% | -97.15% | - | - | - |
| Cost of Goods Sold | 22.18M | 0 | 389K | 0 | 0 | 0 | 815K | 0 | 32K | 28K | 5.4M | 2.25M | 450K | 231K | 93K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | 9.49% | 827.11% | 811.91% | 4.62% | - | - |
| Gross Profit | -22.18M | 0 | -389K | 0 | 0 | 0 | -815K | -1.05M | -32K | 267K | -4.75M | -1.97M | 9.73M | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | 90.51% | -727.11% | -711.91% | 100% | - | - |
| Gross Profit Growth % | - | 100% | - | - | - | 100% | 22.53% | -3187.5% | -111.98% | 105.62% | -140.77% | -120.26% | - | - | - |
| Operating Expenses | 18.46M | 26.57M | 41.64M | 29.16M | 34.64M | 26.99M | 18.48M | 44.35M | 23.08M | 20.45M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | 6933.56% | 10852.07% | 25280.51% | 492.38% | - | - |
| Selling, General & Admin | 15.42M | 13.97M | 13.55M | 11.66M | 12.11M | 9.82M | 4.09M | 16.5M | 8.66M | 5.93M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | 2009.49% | 7537.98% | 18625.99% | 268.61% | - | - |
| Research & Development | 3.04M | 12.61M | 28.48M | 17.5M | 22.53M | 17.17M | 14.39M | 27.84M | 14.43M | 14.53M | 21.64M | 18.43M | 21.78M | 15.8M | 6.32M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | 4924.07% | 3314.09% | 6654.51% | 223.77% | - | - |
| Other Operating Expenses | 0 | 0 | -389K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -40.64M | -26.57M | -42.03M | -29.16M | -34.64M | -26.99M | -19.3M | -45.4M | -23.12M | -20.48M | -81.01M | -72M | -47.93M | -29.13M | -13.53M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | -6943.05% | -12406.13% | -25992.42% | -492.38% | - | - |
| Operating Income Growth % | - | 36.77% | -44.14% | 15.83% | -28.36% | -39.84% | 57.49% | -96.4% | -12.86% | 74.72% | -12.52% | -50.21% | -64.53% | -115.34% | - |
| EBITDA | -40.45M | -26.31M | -41.64M | -28.78M | -34M | -26.61M | -18.48M | -44.35M | -23.08M | -20.45M | -78.77M | -70.71M | -47.48M | -28.9M | -13.53M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | -6933.56% | -12063.4% | -25528.16% | -487.76% | - | - |
| EBITDA Growth % | 6.12% | 36.81% | -44.69% | 15.37% | -27.77% | -43.98% | 58.32% | -92.11% | -12.86% | 74.03% | -11.4% | -48.92% | -64.28% | -113.64% | - |
| D&A (Non-Cash Add-back) | 191K | 266K | 389K | 381K | 638K | 374K | 815K | 1.05M | 32K | 28K | 2.24M | 1.29M | 450K | 231K | 0 |
| EBIT | -40.48M | -26.05M | -40.53M | -28.04M | -34.09M | -27.02M | -19.21M | -44.57M | -27.04M | -84.3M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M |
| Net Interest Income | 124K | 313K | 183K | -334K | -1.07M | -1.28M | 90K | 264K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 147K | 520K | 1.5M | 1.11M | 549K | 1.28K | 90K | 264K | 0 | 0 | 0 | 0 | 0 | 0 | 19K |
| Interest Expense | 23K | 207K | 1.32M | 1.45M | 1.62M | 1.28M | 0 | 0 | 134K | 0 | 659K | 436K | 0 | 0 | 0 |
| Other Income/Expense | 171K | 313K | 183K | -334K | -1.07M | -1.32M | 90K | 831K | -4.06M | -64.1M | -6.45M | -1.15M | -1.59M | 90K | 19K |
| Pretax Income | -40.47M | -26.26M | -41.84M | -29.49M | -35.71M | -28.3M | -19.21M | -44.57M | -27.18M | -84.59M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | -28673.22% | -12566.46% | -26405.78% | -508.68% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -169K | 67K | 201K | 75K | 0 | 90K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.62% | -0.08% | -0.24% | -0.1% | 0% | -0.31% | 0% |
| Net Income | -40.47M | -26.26M | -41.84M | -29.49M | -35.71M | -28.3M | -19.12M | -44.57M | -27.19M | -84.58M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M |
| Net Margin % | - | - | - | - | - | - | - | - | - | -28670.51% | -12597.24% | -26432.85% | -508.68% | - | - |
| Net Income Growth % | 6.1% | 37.24% | -41.88% | 17.41% | -26.17% | -48.04% | 57.1% | -63.9% | 67.85% | -2.82% | -12.35% | -47.86% | -70.5% | -114.98% | - |
| Net Income (Continuing) | -40.47M | -26.26M | -41.84M | -29.49M | -35.71M | -28.3M | -19.21M | -44.57M | -27.18M | -84.59M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.32M | 2.17M | 12.76M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.66 | -6.33 | -1.50 | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72406.33 | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 |
| EPS Growth % | 27.04% | -322% | 21.47% | 39.94% | 59.23% | 98.73% | -1156.02% | 81.5% | 99.64% | -12476.44% | 5.35% | -23.63% | -70.5% | -12284.12% | - |
| EPS (Basic) | - | -6.33 | -1.50 | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72406.33 | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 |
| Diluted Shares Outstanding | 15.22M | 4.15M | 27.9M | 15.42M | 888.38K | 291.56K | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 1.99K |
| Basic Shares Outstanding | 15.22M | 4.15M | 27.9M | 15.42M | 888K | 291K | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 1.99K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying TPST stock.
For fiscal year 2025, Tempest Therapeutics, Inc. (TPST) reported total revenue of $0.0M.
Tempest Therapeutics, Inc. (TPST) reported a net loss of $26.3M for the fiscal year ending 2025.